NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · IEX Real-Time Price · USD
2.230
+0.110 (5.19%)
Jul 22, 2024, 9:58 AM EDT - Market open
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2023. The number of employees decreased by 10 or -58.82% compared to the previous year.
Employees
7
Change (1Y)
-10
Growth (1Y)
-58.82%
Revenue / Employee
n/a
Profits / Employee
-$1,358,307
Market Cap
26.46M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Trinity Biotech | 380 |
Beyond Air | 107 |
Biora Therapeutics | 58 |
HCW Biologics | 45 |
Femasys | 34 |
CytoMed Therapeutics | 27 |
Unity Biotechnology | 19 |
BioVie | 18 |
NNVC News
- 11 days ago - A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides - Accesswire
- 4 weeks ago - A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides - Accesswire
- 4 weeks ago - A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model - Accesswire
- 5 weeks ago - Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect - Accesswire
- 6 weeks ago - The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect - Accesswire
- 2 months ago - Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure - Accesswire
- 2 months ago - NanoViricides Has Filed its Quarterly Report - Accesswire
- 2 months ago - A Novel Broad-Spectrum Antiviral with Activity Against RSV - Accesswire